Joseph J. Krivulka
Mr. Joseph J. Krivulka, also known as Joe, co-founded Akrimax Pharmaceuticals, LLC in 2002. Mr. Krivulka co-founded Triax Pharmaceuticals, LLC and served as its President since November 2004. He has more than 25 years of experience in the pharmaceutical industry. He has extensive expertise in product launches, reformulation and line extensions, clinical development and manufacturing. He served as the Chief Executive Officer of Triax Pharmaceuticals, LLC from November 2004 to May 2011. Mr. Krivulka co-founded Reliant Pharmaceuticals, Inc. and served as its President from 1999 to 2004. He oversaw numerous acquisitions and access to leading brand products from companies such as Novartis, Abbott and Lilly & Co. and built a specialty pharmaceutical sales force in the U.S. of over 1,000 reps. In business development, he negotiated strategic co-promotion partnerships with Biovail Corp., and Amylin Pharmaceuticals. From 1990 to 1997, he served as a Corporate Vice President of Mylan Laboratories Inc., where his mandate was to establish a new strategic direction to have it enter the branded pharmaceutical marketplace. From 1990 to 1997, he served as the Chief Executive Officer of Bertek, Inc. and also served as its President. His role was to identify target companies, products and new chemical/pharmaceutical entitles to create Bertek Pharmaceutical. He successfully brought to market numerous branded products and managed Mylan's entry into the branded pharmaceutical business, with the acquisition of several pharmaceutical companies. His experience also includes strategic business management executive positions with the Janssen Pharmaceutical division of Johnson & Johnson and Sandoz Pharmaceuticals. Since September 2008, he has been the Chairman of the Board of Rouses Point Pharmaceuticals, LLC, which he founded. Mr. Krivulka has been the Chairman of the Board of Akrimax Pharmaceuticals, LLC since January 2008. He has been a Director of Prismic Pharmaceuticals, Inc. since July 1, 2015. He has been an Independent Director of Nektar Therapeutics since March 15, 2005. He serves as a Director at Akrimax. He served as an Independent Director of Ambrilia Biopharma Inc. since May 2006 and Reliant Pharmaceuticals, Inc. He served as a Director of Dance BioPharm Inc. since March 2014. He served as a Director of Aeolus Pharmaceuticals Inc. from June 30, 2004 to May 2013. Mr. Krivulka holds a B.Sc. from West Virginia Wesleyan College and continued his education at Temple University in Physiology.